- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/28 - Antiandrogens
Patent holdings for IPC class A61P 5/28
Total number of patents in this class: 180
10-year publication summary
|
8
|
3
|
4
|
3
|
8
|
6
|
11
|
10
|
9
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Aragon Pharmaceuticals, Inc. | 70 |
9 |
| The University of British Columbia | 1502 |
9 |
| Taisho Pharmaceutical Co., Ltd. | 870 |
6 |
| Suzhou Kintor Pharmaceuticals, Inc. | 59 |
5 |
| University of Tennessee Research Foundation | 758 |
5 |
| Bayer Schering Pharma AG | 384 |
4 |
| British Columbia Cancer Agency Branch | 192 |
4 |
| Provincial Health Services Authority | 188 |
4 |
| Bayer Pharma AG | 1047 |
3 |
| The Johns Hopkins University | 5671 |
3 |
| Fundacio Institut de Recerca Biomedica (irb Barcelona) | 73 |
3 |
| Institucio Catalana de Recerca I Estudis Avancats | 351 |
3 |
| Jiangsu Hengrui Medicine Co., Ltd. | 706 |
3 |
| Sloan-Kettering Institute for Cancer Research | 522 |
3 |
| ESSA Pharma Inc. | 42 |
3 |
| Oncternal Therapeutics, Inc. | 36 |
3 |
| Pfizer Inc. | 3380 |
2 |
| Koninklijke Philips N.V. | 24750 |
2 |
| Sumitomo Chemical Company, Limited | 9049 |
2 |
| Takeda Pharmaceutical Company Limited | 2696 |
2 |
| Other owners | 102 |